Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, a...
Q1 2026
May 13, 2026
FY 2025
Mar 16, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 7, 2025